Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Trends in Outpatient Chemotherapy for Thoracic Oncology].
Fukuda M, Yamaguchi H, Takemoto S, Senju H, Gyotoku H, Dotsu Y, Umeyama Y, Tsuchiya A, Ikeda T, Nose S, Honda T, Kobayashi K, Ishii K, Mukae H, Ashizawa K. Fukuda M, et al. Among authors: takemoto s. Gan To Kagaku Ryoho. 2020 Oct;47(10):1461-1464. Gan To Kagaku Ryoho. 2020. PMID: 33130741 Japanese.
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: takemoto s. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.
Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer.
Takemoto S, Nakamura Y, Fukuda M, Senju H, Gyotoku H, Taniguchi H, Shimada M, Ikeda T, Yamaguchi H, Nakatomi K, Hayashi N, Soda H, Mukae H. Takemoto S, et al. Thorac Cancer. 2017 Nov;8(6):577-581. doi: 10.1111/1759-7714.12483. Epub 2017 Aug 3. Thorac Cancer. 2017. PMID: 28771961 Free PMC article. Clinical Trial.
Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.
Takemoto S, Nakamura Y, Gyoutoku H, Senju H, Ogawara D, Ikeda T, Yamaguchi H, Kitazaki T, Nakano H, Nakatomi K, Tomari S, Sato S, Nagashima S, Fukuda M, Mukae H. Takemoto S, et al. Thorac Cancer. 2019 Mar;10(3):452-458. doi: 10.1111/1759-7714.12958. Epub 2019 Jan 9. Thorac Cancer. 2019. PMID: 30628188 Free PMC article. Clinical Trial.
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer.
Taniguchi H, Yamaguchi H, Dotsu Y, Shimada M, Gyotoku H, Senju H, Takemoto S, Kitazaki T, Fukuda M, Ogawara D, Soda H, Nakatomi K, Sugasaki N, Kinoshita A, Nagashima S, Ikeda T, Nakamura Y, Sakamoto N, Obase Y, Fukuda M, Mukae H. Taniguchi H, et al. Among authors: takemoto s. Thorac Cancer. 2019 Sep;10(9):1764-1769. doi: 10.1111/1759-7714.13134. Epub 2019 Jul 16. Thorac Cancer. 2019. PMID: 31309738 Free PMC article. Clinical Trial.
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M, Yamaguchi H, Fukuda M, Tomono H, Honda N, Dotsu Y, Taniguchi H, Gyotoku H, Senju H, Takemoto S, Ikeda T, Nakatomi K, Nakamura Y, Nagashima S, Yamazaki T, Mukae H. Shimada M, et al. Among authors: takemoto s. Cancer Chemother Pharmacol. 2019 Nov;84(5):1059-1064. doi: 10.1007/s00280-019-03940-0. Epub 2019 Sep 5. Cancer Chemother Pharmacol. 2019. PMID: 31486872 Clinical Trial.
459 results